Skip to main content
SpringerLink
Log in

Antiviral Combination Therapy for Treatment of Chronic Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus Infection

  • Chapter
Antiviral Strategies

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 189))

This chapter reviews the main chemotherapeutic strategies used against human infections caused by agents responsible for the most important chronic viral illnesses, namely hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). There is no doubt that most current knowledge about combination antiviral therapy has been developed in the battle against HIV. The availability of more than 20 antiretroviral drugs has permitted to explore their efficacy when given in combination, an opportunity that unfortunately has only been possible since recent years for chronic hepatitis C and still is in the early stages for chronic hepatitis B. However, new antiviral compounds targeting each of these viruses are developed rapidly and will provide further opportunities to explore the efficacy of combination antiviral therapy. While sufficient suppression of HIV RNA and HBV DNA can only be achieved by long-term administration of potent antiviral drugs, HCV RNA may be completely eradicated from the infected individual after a limited duration of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Afdhal N, Godofsky E, Dienstag J, Rustgi V, Schick L, McEniry D, Zhou XJ, Chao G, Fang C, Fielman B, Myers M, Brown N (2004) Final phase I/II trial results for NM283, a new poly-merase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. Hepatology 40 Suppl 1:726

    Google Scholar 

  • Asahina Y, Izumi N, Enomoto N, Uchihara M, Kurosaki M, Onuki Y, Nishimura Y, Ueda K, Tsuchiya K, Nakanishi H, Kitamura T, Miyake S (2005) Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol 43(4):623–629

    Article  PubMed  CAS  Google Scholar 

  • Barreiro P, Soriano V, Casas E, Gonzalez-Lahoz J (2002) Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. Aids 16(2):245–249

    Article  PubMed  CAS  Google Scholar 

  • Barreiro P, Jimenez-Nacher I, Garcia B, Garcia-Benayas T, Rivas P, Soriano V (2005) Nucle-oside/nucleotide backbones for the treatment of HIV infection. Curr Opin Investig Drugs 6(8):812–822

    PubMed  CAS  Google Scholar 

  • Barreiro P, del Romero J, Leal M, Hernando V, Asencio R, de Mendoza C, Labarga P, Nunez M, Ramos JT, Gonzalez-Lahoz J, Soriano V (2006) Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. J Acquir Immune Defic Syndr 43(3):324–326

    Article  PubMed  Google Scholar 

  • Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, Hopf U, Zeuzem S (2003) Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37(3):600–609

    Article  PubMed  CAS  Google Scholar 

  • Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S (2006) Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130(4):1086–1097

    Article  PubMed  CAS  Google Scholar 

  • Bichko V, Qu l, La Colla M, Tausek M, Bergelson S, Pierra C, Storer R, Gosselin G, Sommadossi JP, Standring D (2005) Characterization of NM283 (Valopicitabine) resistance profile using bovine viral diarrhea. Hepatology 42(1):534A

    Google Scholar 

  • Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, Barbara L (1994) A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 107(3):812–817

    PubMed  CAS  Google Scholar 

  • Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG (2003) An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 361(9359):726–735

    Article  PubMed  CAS  Google Scholar 

  • Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, Chan FK, Hung LC, Lee YT, Tam JS, Lam CW, Sung JJ (2005) A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 142(4):240–250

    PubMed  CAS  Google Scholar 

  • Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, deHertogh D, Wilber R, Colonno R, Apelian D (2006) A comparison of en-tecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354(10):1001–1010

    Article  PubMed  CAS  Google Scholar 

  • Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH (2006) Risk of hepato-cellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1):65–73

    Article  PubMed  CAS  Google Scholar 

  • Clavel F, Hance AJ (2004) HIV drug resistance. N Engl J Med 350(10):1023–1035

    Article  PubMed  CAS  Google Scholar 

  • Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, Wohrmann A, Katlama C, Wilkin T, Haubrich R, Cohen C, Farthing C, Jayaweera D, Markowitz M, Ruane P, Spinosa-Guzman S, Lefebvre E (2007) Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369(9568):1169–1178

    Article  PubMed  CAS  Google Scholar 

  • Colonno R, Rose R, Pokornowski K, Yu C (2007) Four year assessment of ETV resistance in nucleoside-naïve and lamivudine refractory patients. J Hepatol 46 Suppl 1:S294

    Article  Google Scholar 

  • Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ (2006) Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44(6):1656–1665

    Article  PubMed  CAS  Google Scholar 

  • Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, Raknerud N, Bell H (2004) Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 40(6):1260–1265

    Article  PubMed  CAS  Google Scholar 

  • Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J (2003) Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38(3):645–652

    Article  PubMed  CAS  Google Scholar 

  • de Mendoza C, Soriano V (2004) Resistance to HIV protease inhibitors: mechanisms and clinical consequences. Curr Drug Metab 5(4):321–328

    Article  PubMed  Google Scholar 

  • de Mendoza C, Rodriguez C, Colomina J, Tuset C, Garcia F, Eiros JM, Corral A, Leiva P, Aguero J, Torre-Cisneros J, Pedreira J, Viciana I, del Romero J, Saez A, Ortiz de Lejarazu R, Soriano V (2005a) Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin Infect Dis 41(9):1350–1354

    Article  Google Scholar 

  • de Mendoza C, Rodriguez C, Eiros JM, Colomina J, Garcia F, Leiva P, Torre-Cisneros J, Aguero J, Pedreira J, Viciana I, Corral A, del Romero J, Ortiz de Lejarazu R, Soriano V (2005b) Antiretro-viral recommendations may influence the rate of transmission of drug-resistant HIV type 1. Clin Infect Dis 41(2):227–232

    Article  Google Scholar 

  • de Mendoza C, Valer L, Ribera E, Barreiro P, Martin-Carbonero L, Ramirez G, Soriano V (2006) Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients. HIV Clin Trials 7(4):163–171

    Article  PubMed  Google Scholar 

  • de Mendoza C, Morello J, Garcia-Gasco P, Rodriguez-Novoa S, Soriano V (2007) Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients. Expert Opin Pharmacother 8(6):839–850

    Article  PubMed  Google Scholar 

  • Di Bisceglie AM, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, Axiotis CA, Waggoner JG, Park Y, Hoofnagle JH (1992) A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16(3):649–654

    Article  PubMed  Google Scholar 

  • Diago M, Hassanein T, Rodes J, Ackrill AM, Sedarati F (2004) Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin. Ann Intern Med 140(1):72–73

    PubMed  Google Scholar 

  • Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman ZD, Crowther L, Condreay L, Woessner M, Rubin M, Brown NA, for the USLIG (1999) Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256–1263

    Article  PubMed  CAS  Google Scholar 

  • El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fatkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C (2006) CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355(22):2283–2296

    Article  PubMed  CAS  Google Scholar 

  • Embrey MW, Wai JS, Funk TW, Homnick CF, Perlow DS, Young SD, Vacca JP, Hazuda DJ, Felock PJ, Stillmock KA, Witmer MV, Moyer G, Schleif WA, Gabryelski LJ, Jin L, Chen I, Ellis JD, Wong BK, Lin JH, Leonard YM, Tsou NN, Zhuang L (2005) A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells. Bioorg Med Chem Lett 15:4550–4554

    Article  PubMed  CAS  Google Scholar 

  • Fattovich G, Stroffolini T, Zagni I, Donato F (2004). Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127(5) Suppl 1:S35–S50

    Article  PubMed  Google Scholar 

  • Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347(13):975–982

    Article  PubMed  CAS  Google Scholar 

  • Fung SK, Lok AS (2004) Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 40(4):790–792

    PubMed  Google Scholar 

  • Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, Hussain M, Lok AS (2006) Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44(2):283–290

    Article  PubMed  CAS  Google Scholar 

  • Garcia-Gasco P, Blanco F, Soriano V (2005) Integrase inhibitors. J HIV Ther 10(4):75–78

    PubMed  CAS  Google Scholar 

  • Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C (2000) Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32(4 Pt 1):847–851

    Article  PubMed  CAS  Google Scholar 

  • Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL (2003) Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348(9):800–807

    Article  PubMed  CAS  Google Scholar 

  • Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer HC Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM (2004) Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346–355

    PubMed  CAS  Google Scholar 

  • Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA (2006) Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society—USA panel. Top HIV Med 14(3):827–843

    PubMed  Google Scholar 

  • Havlir DV, Richman DD (1996) Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 124(11):984–994

    PubMed  CAS  Google Scholar 

  • Hinrichsen H, Benhamou Y, Wedemeyer H, Reiser M, Sentjens RE, Calleja JL, Forns X, Erhardt A, Cronlein J, Chaves RL, Yong CL, Nehmiz G, Steinmann GG (2004) Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127(5):1347–1355

    Article  PubMed  CAS  Google Scholar 

  • Hofmann WP, Polta A, Herrmann E, Mihm U, Kronenberger B, Sonntag T, Lohmann V, Schonberger B, Zeuzem S, Sarrazin C (2007) Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology 132(3):921–930

    Article  PubMed  CAS  Google Scholar 

  • Hoofnagle JH, Seeff LB (2006) Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 355(23):2444–2451

    Article  PubMed  CAS  Google Scholar 

  • Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW (2005) Pegy-lated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365(9454):123–129

    Article  PubMed  CAS  Google Scholar 

  • Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD (2006) Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 14(3):125–130

    PubMed  Google Scholar 

  • Kieffer T, Sarrazin C, Miller J, Traver S, Zhou Y, Bartels D, Hanzelka B, Muh U, Lin C, Reesink H, Kwong A, Zeuzem S (2006) Combination of telaprevir (VX-950) and PEG-IFN-alfa suppresses both wild-type virus and resistance variants in HCV genotype 1-infected patients in a 14-day phase 1b study. Hepatology 44(4):222A–223A

    Google Scholar 

  • Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF (1998) A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339(2):61–68

    Article  PubMed  CAS  Google Scholar 

  • Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, Lloyd D, Brown NA (2005) A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129(2):528–536

    PubMed  CAS  Google Scholar 

  • Lai CL, Gane E, Hsu CW, Thongsawat S, Wang YM, Chen YG, Heathcote EJ, Rasenack J, Bzowej N, Naoumov N, Zeuzem S, Di Bisceglie A, Chao GC, Constance BAF, Brown NA (2006a) Two-year results from the globe trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs. lamivudine. Hepatology 44(4):222A–222A

    Google Scholar 

  • Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, deHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L (2006b) Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354(10):1011–1020

    Article  CAS  Google Scholar 

  • Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M (2005) Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivu-dine. Hepatology 42(6):1414–1419

    Article  PubMed  CAS  Google Scholar 

  • Lau DTY, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH (2000) Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32(4 Pt 1):828–834

    Article  PubMed  CAS  Google Scholar 

  • Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N (2005) Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352(26):2682–2695

    Article  PubMed  CAS  Google Scholar 

  • Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11(2):97–107

    Article  PubMed  CAS  Google Scholar 

  • Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN (2001) Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33(6):1527–1532

    Article  PubMed  CAS  Google Scholar 

  • Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL (2000) Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119(1):172– 180

    Article  PubMed  CAS  Google Scholar 

  • Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351(15):1521–1531

    Article  PubMed  CAS  Google Scholar 

  • Lindahl K, Stahle L, Bruchfeld A, Schvarcz R (2005) High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 41(2):275–279

    Article  PubMed  CAS  Google Scholar 

  • Lok AS, McMahon BJ (2007) Chronic hepatitis B. Hepatology 45(2):507–539

    Article  PubMed  CAS  Google Scholar 

  • Manesis EK, Papatheodoridis GV, Sevastianos V, Cholongitas E, Papaioannou C, Hadziyannis SJ (2003) Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am J Gastroenterol 98(10):2261–2267

    PubMed  CAS  Google Scholar 

  • Mangia A, Leandro G, Helbling B, Renner EL, Tabone M, Sidoli L, Caronia S, Foster GR, Zeuzem S, Berg T, Di MV, Cino N, Andriulli A (2004) Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. J Hepatol 40(3):478–483

    Article  PubMed  CAS  Google Scholar 

  • Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A (2005) Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352(25):2609–2617

    Article  PubMed  CAS  Google Scholar 

  • Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286):958–965

    Article  PubMed  CAS  Google Scholar 

  • Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL (2003) Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348(9):808–816

    Article  PubMed  CAS  Google Scholar 

  • Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N (2004) Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351(12):1206–1217

    Article  CAS  Google Scholar 

  • McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339(21):1485–1492

    Article  PubMed  CAS  Google Scholar 

  • Mihm U, Herrmann E, Sarrazin C, Zeuzem S (2006) Review article: predicting response in hepatitis C virus therapy. Aliment Pharmacol Ther 23(8):1043–1054

    Article  PubMed  CAS  Google Scholar 

  • Pawlotsky JM (2005) Current and future concepts in hepatitis C therapy. Semin Liver Dis 25(1):72–83

    Article  PubMed  Google Scholar 

  • Poveda E, Rodes B, Labernardiere JL, Benito JM, Toro C, Gonzalez-Lahoz J, Faudon JL, Clavel F, Schapiro J, Soriano V (2004) Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol 74(1):21–28

    Article  PubMed  CAS  Google Scholar 

  • Poveda E, Briz V, Quinones-Mateu M, Soriano V (2006). HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. Aids 20(10):1359–1367

    Article  PubMed  Google Scholar 

  • Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352(9138):1426–1432

    Article  PubMed  CAS  Google Scholar 

  • Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J, McNair L, Purdy S, Chu HM, Jansen PLM (2005) Final results of a phase 1b multiple dose study of VX950, a hepatitis C virus protease inhibitor. Hepatology 42(1):234A

    Google Scholar 

  • Reiser M, Hinrichsen H, Benhamou Y, Reesink HW, Wedemeyer H, Avendano C, Riba N, Yong CL, Nehmiz G, Steinmann GG (2005) Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 41(4):832–835

    Article  PubMed  CAS  Google Scholar 

  • Rodriguez-Novoa S, Barreiro P, Jimenez-Nacher I, Soriano V (2006) Overview of the pharmaco-genetics of HIV therapy. Pharmacogenomics J 6(4):234–245

    PubMed  CAS  Google Scholar 

  • Sarin SK, Sood A, Kumar M, Arora A, Amrapurkar D, Sharma BC, Konar A, Chawla YK, Jain RK, Nanda V, Kumar A, Hissar S, Lavate P, Lahoti D (2007) Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 102(1):96–104

    Article  PubMed  CAS  Google Scholar 

  • Sarrazin C, Kieffer T, Bartels D, Hanzelka B, MÅh U, Welker M, Wincheringer D, Lin C, Grossmann T, Purdy S, Weegink C, Reesink H, Zeuzem S, Kwong A (2005) Characterization of viral variants in the HCV NS3 protease domain of genotype 1 patients that are selected during 14 days of dosing with VX-950. Hepatology 42(1):751A

    Google Scholar 

  • Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, Hussain M, Shah A, Cutler D, Zhang J, Zeuzem S (2007) SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegy-lated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 132(4):1270–1278

    Article  PubMed  CAS  Google Scholar 

  • Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouilleres O, Carbonell N, Loria A, Poupon R (2001) Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology 34(3):573–577

    Article  PubMed  CAS  Google Scholar 

  • Shiffman M, Pappas S, Nyberg L, Greenbloom S, Gibas A, Bacon B, Rasenack J, Suter F, Diago M, Lin A, Soman A, Zeuzem S (2007) Peginterferon alfa-2a plus ribavirin for 16 or 24 weeks in patients with HCV genotype 2 or 3. Final results of the ACCELERATE trial. N Engl J Med 357(2):124–134

    Article  PubMed  CAS  Google Scholar 

  • Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK (1972) Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177(50):705–706

    Article  PubMed  CAS  Google Scholar 

  • Sung JJY, Lai JY, Zeuzem S, Chow WC, Heathcote E, Perrillo R, Brosgart C, Woessner M, Scott SA, Campbell FM (2003) A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): Week 52 analysis. J Hepatol 38:25–26

    Article  Google Scholar 

  • Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF (1999) Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Pre-core Mutant Study Group. Hepatology 29(3):889–896

    Article  PubMed  CAS  Google Scholar 

  • Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA (2006) Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 70(2):28–38

    Article  PubMed  CAS  Google Scholar 

  • von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, Bergk A, Bernsmeier C, Haussinger D, Herrmann E, Zeuzem S (2005) Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129(2):522–527

    Google Scholar 

  • Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte A, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD (2006) Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 166(15):1632–1641

    Article  PubMed  Google Scholar 

  • Wohnsland A, Hofmann WP, Sarrazin C (2007) Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 20(1):23–38

    Article  PubMed  CAS  Google Scholar 

  • Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, Chiu CF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL (2007) A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 56(4):553–559

    Article  PubMed  CAS  Google Scholar 

  • Yuen MF, Lai CL (2006) Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong. Intervirology 49(1–2):96–98

    Article  PubMed  CAS  Google Scholar 

  • Yuen MF, Lai CL (2007) Combination therapy for chronic hepatitis B: simultaneous or sequential? Am J Gastroenterol 102(1):105–106

    Article  PubMed  CAS  Google Scholar 

  • Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ (2000) Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343(23):1666–1672

    Article  PubMed  CAS  Google Scholar 

  • Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Sarrazin C, Harvey J, Brass C, Albrecht J (2004) Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 40(6):993–999

    Article  PubMed  CAS  Google Scholar 

  • Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, Gianfranco E, Vrolijk JM, Esteban JI, Hezode C, Lagging M, Negro F, Soulier A, Verheij-Hart E, Hansen B, Tal R, Ferrari C, Schalm SW, Neumann AU (2005a) International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 43(2):250–257

    Article  CAS  Google Scholar 

  • Zeuzem S, Sarrazin C, Rouzier R, Tarral A, Brion N, Forestier N, Gupta S, Deckman D, Fellows K, Hussain M, Cutler DL, Zhang J (2005b) Anti-viral activity of SCH503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (PEG-IFNalfa). Hepatology 42(1):233A

    Google Scholar 

  • Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, Noviello S, Brass C, Albrecht J (2006) Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44(1):97–103

    Article  PubMed  CAS  Google Scholar 

  • Zoulim F (2006) Antiviral therapy of chronic hepatitis B. Antiviral Res 71(2–3):206–215

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Hospital Carlos III, C/Sinesio Delgado 10, 28029 Madrid, Spain

    Vincent Soriano

  2. Department of Internal Medicine I, Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany

    Stefan Zeuzem

Authors
  1. Wolf Peter Hofmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vincent Soriano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefan Zeuzem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Vincent Soriano or Stefan Zeuzem .

Editor information

Editors and Affiliations

  1. Hygiene Institute Department of Virology, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 324, Heidelberg, 69120, Germany

    Hans-Georg Kräusslich  & Ralf Bartenschlager  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hofmann, W.P., Soriano, V., Zeuzem, S. (2009). Antiviral Combination Therapy for Treatment of Chronic Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus Infection. In: Kräusslich, HG., Bartenschlager, R. (eds) Antiviral Strategies. Handbook of Experimental Pharmacology, vol 189. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-79086-0_12

Download citation

Publish with us

Policies and ethics

Search

Navigation